Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances
Journal article
McMurray, John. (2015). Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. European Journal of Heart Failure. 17(3), pp. 242 - 247. https://doi.org/10.1002/ejhf.250
Authors | McMurray, John |
---|---|
Abstract | This review describes the role of neprilysin (also known as neutral endopeptidase or enkephalinase) in the degradation of natriuretic and other vasoactive peptides, including bradykinin and adrenomedullin. The initial development of neprilysin inhibitors, then angiotensin converting enzyme-neprilysin inhibitors and, most recently, the angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (sacubitril valsartan) as an extension of the nurohumoral basis for the treatment of heart failure is also summarised. Finally, the implications of the compelling benefits of LCZ696 compared with enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) is discussed. |
Year | 2015 |
Journal | European Journal of Heart Failure |
Journal citation | 17 (3), pp. 242 - 247 |
Publisher | John Wiley & Sons |
ISSN | 1388-9842 |
Digital Object Identifier (DOI) | https://doi.org/10.1002/ejhf.250 |
Scopus EID | 2-s2.0-84924331425 |
Page range | 242 - 247 |
Research Group | Mary MacKillop Institute for Health Research |
Publisher's version | File Access Level Controlled |
Place of publication | United Kingdom |
Editors | M. Metra |
https://acuresearchbank.acu.edu.au/item/89945/neprilysin-inhibition-to-treat-heart-failure-a-tale-of-science-serendipity-and-second-chances
Restricted files
Publisher's version
111
total views0
total downloads1
views this month0
downloads this month